Literature DB >> 2798542

Mecamylamine increases nicotine preference and attenuates nicotine discrimination.

J E Rose1, A Sampson, E D Levin, J E Henningfield.   

Abstract

Eight subjects evaluated various qualities of cigarette smoke after being given a range of doses (0, 2.5, 10 and 20 mg) of the nicotinic receptor blocker mecamylamine. In one test condition, subjects were given either high or low nicotine tobacco smoke to determine the effects of mecamylamine on their subjective responses. In another test condition, subjects were allowed to adjust the nicotine dose level of the smoke to determine the effects of mecamylamine on dose preference. When the subjects evaluated puffs of smoke with high and low nicotine content, mecamylamine caused a dose-related decrease in the self-rated strength and harshness of the high nicotine dose level smoke. In contrast, there was little effect on the low dose smoke. At the highest mecamylamine dose (20 mg) there was no significant difference in the ratings of high and low nicotine cigarettes. Low doses of mecamylamine decreased the reported desire for a cigarette, and also attenuated the reduction in desire for a cigarette caused by smoking. When the subjects were allowed to select their preferred level of nicotine intake using a smoke mixing device, the 10 and 20 mg doses of mecamylamine caused a significant increase in self-administered nicotine dose level. Despite this compensatory increase in nicotine self-administration, the reduction in desire for a cigarette after smoking was still less than after placebo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2798542     DOI: 10.1016/0091-3057(89)90061-0

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  27 in total

Review 1.  Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond.

Authors:  Paul R Sanberg; Cecilia Vindrola-Padros; R Douglas Shytle
Journal:  Physiol Behav       Date:  2012-07-06

2.  Mecamylamine attenuates cue-induced reinstatement of nicotine-seeking behavior in rats.

Authors:  Xiu Liu; Anthony R Caggiula; Susan K Yee; Hiroko Nobuta; Alan F Sved; Robert N Pechnick; Russell E Poland
Journal:  Neuropsychopharmacology       Date:  2006-06-21       Impact factor: 7.853

3.  Marshaling the evidence for greater regulation and control of tobacco products: A call for action.

Authors:  R M Kaplan; C T Orleans; K A Perkins; J P Pierce
Journal:  Ann Behav Med       Date:  1995-03

Review 4.  Nicotine and nonnicotine factors in cigarette addiction.

Authors:  Jed E Rose
Journal:  Psychopharmacology (Berl)       Date:  2005-12-16       Impact factor: 4.530

5.  Mutually augmenting interactions of dextromethorphan and sazetidine-A for reducing nicotine self-administration in rats.

Authors:  Edward D Levin; Corrine Wells; Susan Slade; Amir H Rezvani
Journal:  Pharmacol Biochem Behav       Date:  2018-01-31       Impact factor: 3.533

6.  Nicotine as a typical drug of abuse in experimental animals and humans.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2005-10-05       Impact factor: 4.530

7.  Nicotine or tar titration in cigarette smoking behavior?

Authors:  M Hasenfratz; B Baldinger; K Bättig
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Nicotine discrimination in male and female smokers.

Authors:  K A Perkins; A DiMarco; J E Grobe; A Scierka; R L Stiller
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

Review 9.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 10.  Effects of nicotine in experimental animals and humans: an update on addictive properties.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.